1-20 of 23
subcutaneous injections
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B. Bolli, Carmine G. Fanelli
Journal: Diabetes Care
Diabetes Care 2019;42(1):85–92
https://doi.org/10.2337/dc18-0706
Published: 10 October 2018
View article titled, Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes
Open the PDF for Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S41–S48

Jordan E. Pinsker, Tom Shank, Eyal Dassau, David Kerr
Journal: Diabetes Care
Diabetes Care 2015;38(10):e174
https://doi.org/10.2337/dc15-0839
Published: 15 September 2015
View article titled, Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <em>Standards of Medical Care in Diabetes—2015</em>. Diabetes Care 2015;38(Suppl. 1):S41–S48
Open the PDF for Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <em>Standards of Medical Care in Diabetes—2015</em>. Diabetes Care 2015;38(Suppl. 1):S41–S48 in another window
Journal Articles

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection

Paola Lucidi, Francesca Porcellati, Anna Marinelli Andreoli, Ilaria Carriero, Paola Candeloro, Patrizia Cioli, Geremia B. Bolli, Carmine G. Fanelli
Journal: Diabetes Care
Diabetes Care 2015;38(12):2204–2210
https://doi.org/10.2337/dc15-0801
Published: 10 September 2015
View article titled, Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection
Open the PDF for Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection in another window
Includes: Supplementary data
Journal Articles

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

Paola Lucidi, MD, Francesca Porcellati, MD, Paolo Rossetti, MD, Paola Candeloro, PHD, Anna Marinelli Andreoli, MD, Patrizia Cioli, RD, Annke Hahn, PHD, Ronald Schmidt, PHD, Geremia B. Bolli, MD, Carmine G. Fanelli, MD
Journal: Diabetes Care
Diabetes Care 2012;35(12):2647–2649
https://doi.org/10.2337/dc12-0271
Published: 14 November 2012
View article titled, Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes
Open the PDF for Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Geremia B. Bolli, MD, Annke D. Hahn, PHD, Ronald Schmidt, PHD, Tanja Eisenblaetter, PHD, Raphael Dahmen, MD, Tim Heise, MD, Reinhard H.A. Becker, MD
Journal: Diabetes Care
Diabetes Care 2012;35(12):2626–2630
https://doi.org/10.2337/dc12-0270
Published: 14 November 2012
View article titled, Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
Open the PDF for Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis

Filip K. Knop, MD, Tina Vilsbøll, MD, Steen Larsen, MD, DMSC, Sten Madsbad, MD, DMSC, Jens J. Holst, MD, DMSC, Thure Krarup, MD, DMSC
Journal: Diabetes Care
Diabetes Care 2003;26(9):2581–2587
https://doi.org/10.2337/diacare.26.9.2581
Published: 01 September 2003
View article titled, No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis
Open the PDF for No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis in another window
Journal Articles

Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects

Carol Homko, RN, PHD, Antonio Deluzio, DO, Carolyn Jimenez, PHD, Jerzy W. Kolaczynski, MD, PHD, Guenther Boden, MD
Journal: Diabetes Care
Diabetes Care 2003;26(7):2027–2031
https://doi.org/10.2337/diacare.26.7.2027
Published: 01 July 2003
View article titled, Comparison of Insulin Aspart and Lispro: <subtitle>Pharmacokinetic and metabolic effects</subtitle>
Open the PDF for Comparison of Insulin Aspart and Lispro: <subtitle>Pharmacokinetic and metabolic effects</subtitle> in another window
Journal Articles

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Bodil Elbrønd, MD, Grethe Jakobsen, MSC, Søren Larsen, MSC, Henrik Agersø, PHD, Lisbeth Bjerring Jensen, PHD, Paul Rolan, MD, Jeppe Sturis, PHD, Vibeke Hatorp, MSC, Milan Zdravkovic, PHD
Journal: Diabetes Care
Diabetes Care 2002;25(8):1398–1404
https://doi.org/10.2337/diacare.25.8.1398
Published: 01 August 2002
View article titled, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects
Open the PDF for Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects in another window
Journal Articles

Leukocytoclastic Vasculitis Induced by Subcutaneous Injection of Human Insulin in a Patient With Type 1 Diabetes and Essential Thrombocytemia

Thomas Mandrup-Poulsen, MD, PhD, Jens Mølvig, MD, PhD, Julie Pildal, MD, Åse Krogh Rasmussen, MD, PhD, Lennart Andersen, MSC, Birgit Guldhammer Skov, MD, PhD, Jørgen Petersen, MD, PhD
Journal: Diabetes Care
Diabetes Care 2002;25(1):242–243
https://doi.org/10.2337/diacare.25.1.242
Published: 01 January 2002
View article titled, Leukocytoclastic Vasculitis Induced by Subcutaneous Injection of Human Insulin in a Patient With Type 1 Diabetes and Essential Thrombocytemia
Open the PDF for Leukocytoclastic Vasculitis Induced by Subcutaneous Injection of Human Insulin in a Patient With Type 1 Diabetes and Essential Thrombocytemia in another window
Journal Articles

Glucodynamics and Pharmacokinetics of 70/30 vs. 50/50 NPH/Regular Insulin Mixtures After Subcutaneous Injection

Esther I. Krug, MD, Louise DeRiso, CRNP, Mary Beth Tedesco, CRNP, Harsha Rao, MD, Mary T. Korytkowski, MD
Journal: Diabetes Care
Diabetes Care 2001;24(9):1694–1695
https://doi.org/10.2337/diacare.24.9.1694
Published: 01 September 2001
View article titled, Glucodynamics and Pharmacokinetics of 70/30 vs. 50/50 NPH/Regular Insulin Mixtures After Subcutaneous Injection
Open the PDF for Glucodynamics and Pharmacokinetics of 70/30 vs. 50/50 NPH/Regular Insulin Mixtures After Subcutaneous Injection in another window
Journal Articles

Direct Comparison of Insulin Lispro and Aspart Shows Small Differences in Plasma Insulin Profiles After Subcutaneous Injection in Type 1 Diabetes

Christina A. Hedman, MD, Torbjörn Lindström, MD, PHD, Hans J. Arnqvist, MD
Journal: Diabetes Care
Diabetes Care 2001;24(6):1120–1121
https://doi.org/10.2337/diacare.24.6.1120
Published: 01 June 2001
View article titled, Direct Comparison of Insulin Lispro and Aspart Shows Small Differences in Plasma Insulin Profiles After Subcutaneous Injection in Type 1 Diabetes
Open the PDF for Direct Comparison of Insulin Lispro and Aspart Shows Small Differences in Plasma Insulin Profiles After Subcutaneous Injection in Type 1 Diabetes in another window
Meeting Abstracts

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

D R Owens, P A Coates, S D Luzio, J P Tinbergen, R Kurzhals
Journal: Diabetes Care
Diabetes Care 2000;23(6):813–819
https://doi.org/10.2337/diacare.23.6.813
Published: 01 June 2000
View article titled, Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
Open the PDF for Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. in another window
Journal Articles

Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function

Simone Pampanelli, MD, Elisabetta Torlone, MD, Carlo Ialli, MD, Paola Del Sindaco, MD, Marco Ciofetta, MD, Mauro Lepore, MD, Linda Bartocci, MD, Paolo Brunetti, MD, Geremia B Bolli, MD
Journal: Diabetes Care
Diabetes Care 1995;18(11):1452–1459
https://doi.org/10.2337/diacare.18.11.1452
Published: 01 November 1995
View article titled, Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function
Open the PDF for Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function in another window
Journal Articles

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

Mark K Gutniak, MD, PHD, Birgitta Linde, MD, PHD, Jens J Holst, MD, PHD, Suad Efendić, MD, PHD
Journal: Diabetes Care
Diabetes Care 1994;17(9):1039–1044
https://doi.org/10.2337/diacare.17.9.1039
Published: 01 September 1994
View article titled, Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM
Open the PDF for Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM in another window
Journal Articles

A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes

Marie-Joelle Haardt, MD, Jean-Louis Selam, MD, Gerard Slama, MD, Jean-Pierre Bethoux, MD, Catherine Dorange, MD, Brigitte Mace, RN, Marie-Lou Ramaniche, RN, Françoise Bruzzo, BS
Journal: Diabetes Care
Diabetes Care 1994;17(8):847–851
https://doi.org/10.2337/diacare.17.8.847
Published: 01 August 1994
View article titled, A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes
Open the PDF for A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes in another window
Journal Articles

Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects

John P Bantle, MD, Lonzetta Neal, MD, Lisa M Frankamp, RN
Journal: Diabetes Care
Diabetes Care 1993;16(12):1592–1597
https://doi.org/10.2337/diacare.16.12.1592
Published: 01 December 1993
View article titled, Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects
Open the PDF for Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects in another window
Journal Articles

Devices for Insulin Administration

Jean-Louis Selam, MD, M Arthur Charles, MD, PhD
Journal: Diabetes Care
Diabetes Care 1990;13(9):955–979
https://doi.org/10.2337/diacare.13.9.955
Published: 01 September 1990
View article titled, Devices for Insulin Administration
Open the PDF for Devices for Insulin Administration in another window
Journal Articles

Absorption Kinetics and Action Profiles After Sequential Subcutaneous Administration of Human Soluble and Lente Insulin Through one Needle

Henk J Bilo, MD, Robert J Heine, MD, Anneke C Sikkenk, MD, Jan van der Meer, MD, ED A van der Veen, MD
Journal: Diabetes Care
Diabetes Care 1987;10(4):466–469
https://doi.org/10.2337/diacare.10.4.466
Published: 01 July 1987
View article titled, Absorption Kinetics and Action Profiles After Sequential Subcutaneous Administration of Human Soluble and Lente Insulin Through one Needle
Open the PDF for Absorption Kinetics and Action Profiles After Sequential Subcutaneous Administration of Human Soluble and Lente Insulin Through one Needle in another window
Journal Articles

Dissociation of Insulin Absorption and Blood Flow During Massage of a Subcutaneous Injection Site

B Linde, MD
Journal: Diabetes Care
Diabetes Care 1986;9(6):570–574
https://doi.org/10.2337/diacare.9.6.570
Published: 01 November 1986
View article titled, Dissociation of Insulin Absorption and Blood Flow During Massage of a Subcutaneous Injection Site
Open the PDF for Dissociation of Insulin Absorption and Blood Flow During Massage of a Subcutaneous Injection Site in another window
Journal Articles

Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus

Giatgen A Spinas, M.D., Andreas Bock, M.D., Ulrich Keller, M.D.
Journal: Diabetes Care
Diabetes Care 1985;8(5):429–435
https://doi.org/10.2337/diacare.8.5.429
Published: 01 September 1985
View article titled, Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus
Open the PDF for Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus in another window